Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Primary Antiphospholipid Syndrome with Livedo Reticularis is Linked to Female Sex and Stroke and Negatively Associated with Thyroid Disease

Author(s): Jozélio Freire Carvalho*, Roberto Paulo Correia de Araujo and Thelma Larocca Skare

Volume 18, Issue 4, 2022

Published on: 12 April, 2022

Page: [352 - 356] Pages: 5

DOI: 10.2174/1573397117666211116111322

Price: $65

conference banner
Abstract

Aims: To study the clinical and laboratory findings between patients with primary Antiphospholipid Syndrome (pAPS) with and without LR.

Background: Livedo Reticularis (LR) is a common manifestation of Antiphospholipid Syndrome (APS). Although no previous study evaluated patients with and without LR.

Methods: A transversal study including 66 pAPS patients was performed. Demographical, anthropometric, medication use, antiphospholipid antibodies profile data were evaluated, and LR's clinical and laboratory features. Patients were subdivided into one of two groups: pAPS with LR and pAPS without LR.

Results: Both groups were alike concerning demographics and anthropometrics. Interestingly, the frequency of stroke (28.5 vs. 7.5%, p=0.04), as well as of Sneddon’s syndrome (100 vs. 30.0%, p<0.0001), were higher in pAPS with LR than the other group. Conversely, patients in the pAPS without LR group had more thyroidopathy than those in the pAPS with LR group (80% vs. 50% %, p=0.03).

Conclusion: Patients with pAPS and LR have more stroke and seem to be protected from thyroidopathy. Careful follow-up of these patients is therefore advised.

Keywords: Antiphospholipid syndrome, livedo reticularis, Sneddon’s syndrome, stroke, thrombosis, antiphospholipid antibodies, thyroidopathy.

« Previous Next »
Graphical Abstract

[1]
Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed) 1983; 287(6399): 1088-9.
[http://dx.doi.org/10.1136/bmj.287.6399.1088] [PMID: 6414579]
[2]
Criado PR, Faillace C, Magalhães LS, Brito K, de Carvalho JF. Livedo reticular: classificação, causas e diagnósticos diferenciais. Acta Reumatol Port 2012; 37(3): 218-25.
[PMID: 23348110]
[3]
Pincelli MS, Echavarria AMJ, Criado PR, et al. Livedo Racemosa: Clinical, laboratory, and histopathological findings in 33 patients. Int J Low Extrem Wounds 2021; 20(1): 22-8.
[http://dx.doi.org/10.1177/1534734619896938] [PMID: 31996060]
[4]
Caldas CA, de Carvalho JF. Primary antiphospholipid syndrome with and without Sneddon’s syndrome. Rheumatol Int 2011; 31(2): 197-200.
[http://dx.doi.org/10.1007/s00296-009-1310-z] [PMID: 20012621]
[5]
Francès C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore) 1999; 78(4): 209-19.
[http://dx.doi.org/10.1097/00005792-199907000-00001] [PMID: 10424203]
[6]
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite Antiphospholipid Syndrome (APS). J Thromb Haemost 2006; 4(2): 295-306.
[http://dx.doi.org/10.1111/j.1538-7836.2006.01753.x] [PMID: 16420554]
[7]
Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285(19): 2486-97.
[http://dx.doi.org/10.1001/jama.285.19.2486] [PMID: 11368702]
[8]
Rashtak S, Pittelkow MR. Skin involvement in systemic autoimmune diseases. Curr Dir Autoimmun 2008; 10: 344-58.
[http://dx.doi.org/10.1159/000131754] [PMID: 18460895]
[9]
Bolayir E, Yilmaz A, Kugu N, Erdogan H, Akyol M, Akyuz A. Sneddon’s syndrome: Clinical and laboratory analysis of 10 cases. Acta Med Okayama 2004; 58(2): 59-65.
[PMID: 15255506]
[10]
Krause I, Leibovici L, Blank M, Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 2007; 16(3): 176-80.
[http://dx.doi.org/10.1177/0961203306075977] [PMID: 17432102]
[11]
Asherson RA, Cervera R. The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis 1992; 51(2): 147-50.
[http://dx.doi.org/10.1136/ard.51.2.147] [PMID: 1550393]
[12]
Gibson GE, Su WP, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol 1997; 36(6 Pt 1): 970-82.
[http://dx.doi.org/10.1016/S0190-9622(97)80283-6] [PMID: 9204065]
[13]
Shoenfeld Y, Zandman-Goddard G, Stojanovich L, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008; 10(1): 8-12.
[PMID: 18300563]
[14]
Zandman-Goddard G, Peeva E, Shoenfeld Y. Gender and autoimmunity. Autoimmun Rev 2007; 6(6): 366-72.
[http://dx.doi.org/10.1016/j.autrev.2006.10.001] [PMID: 17537382]
[15]
Fazeli B, Dadgar Moghadam M, Niroumand S. How to treat a patient with thromboangiitis Obliterans: A systematic review. Ann Vasc Surg 2018; 49: 219-28.
[http://dx.doi.org/10.1016/j.avsg.2017.10.022] [PMID: 29421414]
[16]
de Carvalho JF, Pasoto SG, Appenzeller S. Seizures in primary antiphospholipid syndrome: The relevance of smoking to stroke. Clin Dev Immunol 2012; 2012: 981519.
[http://dx.doi.org/10.1155/2012/981519] [PMID: 22489254]
[17]
Liel Y. Livedo reticularis: A rare manifestation of Graves hyperthyroidism associated with anticardiolipin antibodies. South Med J 2004; 97(6): 601-3.
[http://dx.doi.org/10.1097/00007611-200406000-00019] [PMID: 15255431]
[18]
Picascia DD, Pellegrini JR. Livedo reticularis. Cutis 1987; 39(5): 429-32.
[PMID: 3581915]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy